Last reviewed · How we verify
NCT03170063: SAVE001
FoxBioNet Pilot Project: SAVE (Synuclein Assay Validation Effort)
trial testing Procedure/Surgery: Biofluid samplings in Parkinson Disease in 54 participants. Completed in 12 March 2018.
12 March 2018
Quick facts
| Lead sponsor | Michael J. Fox Foundation for Parkinson's Research |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 54 |
| Start date | 8 August 2017 |
| Primary completion | 12 March 2018 |
| Estimated completion | 12 March 2018 |
| Sites | 5 locations across United States |
Drugs / interventions tested
- Procedure/Surgery: Biofluid samplings
Conditions studied
- Parkinson Disease — all drugs for Parkinson Disease →
Sponsor
Michael J. Fox Foundation for Parkinson's Research
Who can join
30 and older, any sex, with Parkinson Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall objective of this study is to compare the performance of available oligomeric and phosphorylated a-synuclein assay in cerebrospinal fluid and blood.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
"Janus-Faced" α-Synuclein: Role in Parkinson's Disease.
Ray B, Mahalakshmi AM, Tuladhar S, Bhat A, et al · · 2021 · cited 7× · PMID 34124057 · DOI 10.3389/fcell.2021.673395
Verify or expand the search:
- PubMed search for NCT03170063
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Parkinson Disease
Currently open trials in the same condition.
- NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
- NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
- NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
- NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
- NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting
Other Michael J. Fox Foundation for Parkinson's Research trials
Trials by the same sponsor.
- NCT04906590 — PPMI Tau PET Imaging · Phase 2 · completed
- NCT04603326 — FoxBioNet: ECV (Extracellular Vesicle) 004 · completed
- NCT06719583 — Black and African Americans Connections to Parkinson's Disease (BLAAC PD) · recruiting
- NCT03775447 — Fox BioNet Project: ECV-003 · completed
- NCT03545425 — Fox BioNet Project: LRRK2-002 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03170063 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Michael J. Fox Foundation for Parkinson's Research
- Last refreshed: 20 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03170063.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing